The fibrosis drug developer has passed a clinical milestone to trigger the final part of a series B round backed by Pfizer, Novartis and Bristol-Myers Squibb.
US-based fibrosis treatment developer Blade Therapeutics yesterday secured the final tranche of the $45m series B round it announced in June 2016, which features pharmaceutical firms Pfizer, Novartis and Bristol-Myers Squibb.
Healthcare investment firm Deerfield Management led the round, which included Osage University Partners and MPM Capital. Pfizer took part through its corporate venturing arm, Pfizer Venture Investments, while Novartis participated through its Novartis Institutes of Biomedical Research division.
The terms of the round stipulated that Blade Therapeutics would…
